Focused On-demand Library for Radial spoke head 1 homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8WYR4

UPID:

RSPH1_HUMAN

Alternative names:

Cancer/testis antigen 79; Male meiotic metaphase chromosome-associated acidic protein; Meichroacidin; Testis-specific gene A2 protein

Alternative UPACC:

Q8WYR4; A8MWV0; B2RBN9; Q3MJA1

Background:

Radial spoke head 1 homolog (RSPH1), also known as Cancer/testis antigen 79, plays a crucial role in the motility of sperm and cilia by functioning as part of axonemal radial spoke complexes. This protein is pivotal in ensuring the proper movement and function of motile cilia, which are essential for various physiological processes.

Therapeutic significance:

Mutations in RSPH1 are linked to Ciliary dyskinesia, primary, 24, a disorder characterized by recurrent respiratory infections and chronic inflammation due to defects in respiratory cilia. Understanding the role of RSPH1 could open doors to potential therapeutic strategies for treating respiratory conditions stemming from ciliary dysfunction.